Search

Antihemophilic factor (recombinant), PEGylated

PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. … PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529].

Isavuconazonium

[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251] … Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration.

Acetazolamide

Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition … It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual

Galcanezumab

[A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache. … [A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses

Natalizumab

In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.

Evolocumab

Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. … It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.

Tozinameran

It is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19. … from one individual to another.

Cloxacillin

A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

Nivolumab

[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. … [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.